Here, we identified four novel variants in the SLCO2A1 gene and demonstrated that gastric mucosa hyperplasia might be a common clinical manifestation of PDP and celecoxib would be a considerable treatment for PDP patients. This evidence concerns the gene SLCO2A1 and primary hypertrophic osteoarthropathy.